Answers are grounded in this paper and cite their sources.
Feasibility study demonstrates tumor uptake values on dedicated breast PET/MRI match whole-body scans within a 10% margin in breast cancer patients, supporting single-session dual imaging.
BACKGROUND: [ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG)-PET/MRI is a 'one-stop-shop' combination that enriches lesion characterization, locoregional and distant staging in breast cancer patients. The combination consists of a breast (bpPET/MRI) and whole-body (wbPET/MRI) within a single protocol. Despite acceptable test-retest reproducibility of standardized uptake value (SUV) in PET examinations being 10%, limited knowledge concerning agreement between metabolic parameters from each protocol (bpPET/MRI and wbPET/MRI) is available. OBJECTIVE: Feasibility study to verify whether differences of metabolic parameters in breast tumor, on prone bpPET/MRI acquired between 30 and 55 min postinjection, and compared to wbPET/MRI at 60 min, remained within the 10% margin acceptable in clinical practice. METHODS: Breast cancer patients underwent [ 18 F]FDG-PET/MRI: bpPET/MRI and wbPET/MRI. Maximum SUV (SUVmax) and mean SUV (SUVmean) measurements of the index tumor, contralateral breast, liver, and blood pool were obtained from bpPET/MRI images acquired every 5 min between 30 and 55 min. These values were compared with wbPET/MRI SUVs at 60 min (reference). RESULTS: Twenty patients were included. The majority of PET/MRI exams remained within the 10% margin at all timepoints. At 45 and 50 min the mean percentage difference of SUVmax and SUVmean compared to 60 min was less than 1.3-3.6%. Other SUV measurements remained within 10% margin in majority of cases, while bloodpool SUVs did differ. CONCLUSION: Metabolic parameters for local staging in the index tumor on bpPET/MRI may be considered comparable to the metabolic parameters retrieved from wbPET/MRI in breast cancer patients. These findings reinforce the potential of a breast-dedicated protocol integrated in the whole-body [ 18 F]FDG PET/MRI in breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Elferen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: